http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Battery Charging System for PHEV and EV using Single Phase AC/DC PWM Buck Converter
Jung-Hyo Lee,Doo-Yong Jung,Sang-HoonPark,Taek-Kie Lee,Young-Ryul Kim,Chung-Yuen Won 대한전기학회 2012 Journal of Electrical Engineering & Technology Vol.7 No.5
In this paper, a battery charging system for Plug-in Hybrid Electric Vehicle (PHEV) and Electric Vehicle (EV), and operation algorithm of charging system are introduced. Also, the proposed charging system uses commercial electricity in order to charge the battery of parked PHEV and 48V battery charging system with power factor controllable single phase converter for PHEV is investigated in this paper. This research verifies the power factor control of input and the converter output controlled by the charge control algorithm through simulation and experiment.
Da Eun Woo,Jae Min Lee,김유경,Yong-HoonPark 대한소아청소년과학회 2016 Clinical and Experimental Pediatrics (CEP) Vol.59 No.2
Patients with hemolytic-uremic syndrome (HUS) can rapidly develop profound anemia as the disease progresses, as a consequence of red blood cell (RBC) hemolysis and inadequate erythropoietin synthesis. Therefore, RBC transfusion should be considered in HUS patients with severe anemia to avoid cardiac or pulmonary complications. Most patients who are Jehovah’s Witnesses refuse blood transfusion, even in the face of life-threatening medical conditions due to their religious convictions. These patients require management alternatives to blood transfusions. Erythropoietin is a glyco- peptide that enhances endogenous erythropoiesis in the bone marrow. With the availability of re- combinant human erythropoietin (rHuEPO), several authors have reported its successful use in patients refusing blood transfusion. However, the optimal dose and duration of treatment with rHuEPO are not established. We report a case of a 2-year-old boy with diarrhea-associated HUS whose family members are Jehovah’s Witnesses. He had severe anemia with acute kidney injury. His lowest hemoglobin level was 3.6 g/dL, but his parents refused treatment with packed RBC transfusion due to their religious beliefs. Therefore, we treated him with high-dose rHuEPO (300 IU/kg/day) as well as folic acid, vitamin B12, and intravenous iron. The hemoglobin level increased steadily to 7.4 g/dL after 10 days of treatment and his renal function improved without any complications. To our knowledge, this is the first case of successful rHuEPO treatment in a Jehovah’s Witness child with severe anemia due to HUS.